GYN | ACE Trial for Overactive Bladder

Study Brief | The purpose of the ACE trial is to assess cognitive function in women taking an anticholinergic medication (trospium) for the treatment of overactive bladder. This medication is FDA-approved and is not experimental. There are rare reports of changes in cognitive function when taking any anticholinergic medication for overactive bladder. The goal is to administer written cognitive function tests to measure your cognitive function before and after starting medication.

Principal Investigator

Name: ACE: The Effect of Anticholinergics on Cognitive Function in the Elderly: a Randomized Controlled Trial

Principal Investigator: Dr. Elizabeth Geller

Recruitment Length: August 2013- May 2014

Participation Details: Participation will include a baseline visit, a 1-week visit and 4-week follow-up visit. The 1-week visit will be only for research purposes but the 4-week visit will occur at the time of your follow-up visit with your healthcare provider.

Compensation Available: Participants will receive one month’s supply of free medication for taking part in this study.  They will also receive a parking voucher for the 1-week visit since this trip to UNC is for research purposes only.

Qualifiers for the study: Participants must be:

  • Women ≥ 65 years
  • Diagnosed with overactive bladder 
  • Interested in trying medication for this condition

Online Interest Form 
Study Coordinator Phone:  919-843-8359

IRB Approval Number: 13-1352

Filed under: ,